Home » Stocks » NRBO

NeuroBo Pharmaceuticals, Inc. (NRBO)

Stock Price: $6.03 USD -0.15 (-2.43%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 118.62M
Revenue (ttm) n/a
Net Income (ttm) -21.33M
Shares Out 16.43M
EPS (ttm) 13.03
PE Ratio 0.46
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.03
Previous Close $6.18
Change ($) -0.15
Change (%) -2.43%
Day's Open 6.13
Day's Range 5.84 - 6.21
Day's Volume 39,979
52-Week Range 5.02 - 30.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutic...

Zacks Investment Research - 4 weeks ago

NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

PRNewsWire - 2 months ago

BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifyi...

PRNewsWire - 5 months ago

BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.

PRNewsWire - 7 months ago

BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifyi...

About NRBO

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered i... [Read more...]

Industry
Biotechnology
CEO
Dr. Jeong Gu Kang Ph.D.
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 25.00.

Price Target
$25.00
Analyst Consensus: Buy